Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–41.
Article CAS PubMed PubMed Central Google Scholar
Bell M, Gottschalk S. Engineered cytokine signaling to improve CAR T cell effector function. Front Immunol. 2021;12:684642.
Article CAS PubMed PubMed Central Google Scholar
Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32:51–82.
Article CAS PubMed Google Scholar
Wieser R, Attisano L, Wrana JL, Massagué J. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol. 1993;13:7239–47.
CAS PubMed PubMed Central Google Scholar
Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171–81.
Article CAS PubMed Google Scholar
Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7:1118–22.
Article CAS PubMed Google Scholar
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855–66.
Article CAS PubMed PubMed Central Google Scholar
Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, et al. TGF-β/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. Int J Mol Sci. 2021;22:8706.
Article CAS PubMed PubMed Central Google Scholar
Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5:e133977.
Article PubMed PubMed Central Google Scholar
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724–34.
Article CAS PubMed PubMed Central Google Scholar
Liang, S, Zheng R, Zuo B, Li J, Wang Y, Han Y, et al. SMAD7 expression improves the persistent and safety of CAR T cells for solid tumors. Cell Mol Immunol. 2024;21:213–26.
Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK, et al. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol. 2007;8:504–13.
Article CAS PubMed Google Scholar
Li G, Liao G, Xie J, Liu B, Li X, Qiu M. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer. Respirology. 2023;28:869–80.
Tu E, Chia C, Chen W, Zhang D, Park SA, Jin W, et al. T cell receptor-regulated TGF-β type I receptor expression determines T cell quiescence and activation. Immunity. 2018;48:745–59.e6.
Comments (0)